Teachers Retirement System of The State of Kentucky Acquires 72,700 Shares of DexCom, Inc. $DXCM

Teachers Retirement System of The State of Kentucky raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 30.4% in the 1st quarter, HoldingsChannel.com reports. The firm owned 311,905 shares of the medical device company’s stock after buying an additional 72,700 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in DexCom were worth $19,588,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Reflection Asset Management purchased a new position in shares of DexCom in the 4th quarter worth approximately $25,000. Ascentis Independent Advisors bought a new stake in DexCom during the first quarter worth $25,000. CVA Family Office LLC lifted its holdings in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares during the period. MCF Advisors LLC purchased a new position in DexCom in the fourth quarter worth $32,000. Finally, ORG Partners LLC boosted its position in DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

DexCom stock opened at $76.35 on Tuesday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $29.46 billion, a PE ratio of 32.63, a price-to-earnings-growth ratio of 1.23 and a beta of 1.45. The firm’s 50 day simple moving average is $69.95 and its 200 day simple moving average is $68.51.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the business earned $0.32 earnings per share. The firm’s revenue was up 15.0% on a year-over-year basis. As a group, analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares in the company, valued at approximately $8,034,969.15. The trade was a 1.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total transaction of $358,576.00. Following the completion of the sale, the executive vice president directly owned 100,361 shares of the company’s stock, valued at $7,326,353. This represents a 4.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,450 shares of company stock worth $5,270,409 in the last quarter. 0.28% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on DXCM shares. TD Cowen restated a “buy” rating and set a $95.00 price target (up from $75.00) on shares of DexCom in a research report on Wednesday, June 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $88.00 price objective (up from $75.00) on shares of DexCom in a research report on Monday, June 15th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of DexCom in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 target price on the stock. Benchmark reaffirmed a “buy” rating on shares of DexCom in a report on Tuesday, June 23rd. Finally, Stifel Nicolaus set a $90.00 price objective on DexCom and gave the company a “buy” rating in a research note on Friday, June 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average target price of $84.88.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.